| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 67051 |
Mal-PEG4-Val-Ala-PAB，可降解的ADC（抗体偶联药物）连接子 |
144 |
WYQ |
2024-12-19 |
| 67052 |
Mal-PEG1-Val-Cit-OH的介绍 |
120 |
zyl |
2024-12-19 |
| 67053 |
MC-vc-PAB-Monomethyl dolastatin10， ADC试剂 |
82 |
kx |
2024-12-19 |
| 67054 |
CAS: 1870916-87-2，Mal-Val-Ala-PAB，马来酰亚胺-缬氨酸-丙氨酸-对氨基苯甲酸 |
86 |
WYQ |
2024-12-19 |
| 67055 |
cas:2395887-69-9 Mal-PEG2-Val-Cit-PAB-PNP |
82 |
zyl |
2024-12-19 |
| 67056 |
SuO-Val-Cit-PAB-MMAE， ADC试剂 |
73 |
kx |
2024-12-19 |
| 67057 |
Mal-PEG4-Val-Ala-PAB-PNP的介绍 |
85 |
zyl |
2024-12-19 |
| 67058 |
CAS: 2348405-93-4，DBCO-PEG4-Val-Ala-PAB-PNP |
61 |
WYQ |
2024-12-19 |
| 67059 |
CAS: 2348405-92-3，DBCO-PEG4-Val-Ala-PAB |
72 |
WYQ |
2024-12-19 |
| 67060 |
cas:2112738-13-1 Mal-amido-PEG2-Val-Cit-PAB-PNP |
72 |
zyl |
2024-12-19 |
| 67061 |
Azido-PEG4-Val-Ala-PAB，分子式：C29H48N8O9 |
64 |
WYQ |
2024-12-19 |
| 67062 |
cas:2055896-86-9，MC-Val-Cit-PAB-tubulysin5a ， ADC试剂 |
80 |
kx |
2024-12-19 |
| 67063 |
Azido-PEG8-Val-Cit-PAB-PNP |
58 |
zyl |
2024-12-19 |
| 67064 |
cas:2055896-83-6，MC-Val-Cit-PAB-carfilzomib ， ADC试剂 |
103 |
kx |
2024-12-19 |
| 67065 |
MAL-di-EG-Val-Cit-PAB-MMAF， ADC试剂 |
71 |
kx |
2024-12-19 |
| 67066 |
cas:2353409-45-5 endo BCN-PEG3-VC-PFP Ester |
80 |
zyl |
2024-12-19 |
| 67067 |
Hydrazone-doxorubicin， ADC试剂 |
147 |
kx |
2024-12-19 |
| 67068 |
DBCO-C4-Val-Cit-PABC-PNP |
60 |
zyl |
2024-12-19 |
| 67069 |
cas:644981-35-1 Val-Cit-PAB-MMAE |
71 |
zyl |
2024-12-19 |
| 67070 |
cas:170908-81-3，DOTA-NHS ester ，1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 1-(2,5-二氧代-1-吡咯烷基)酯 |
64 |
kx |
2024-12-19 |
| 67071 |
endo-BCN-PEG4-Val-Cit-PAB-MMAE的介绍 |
72 |
zyl |
2024-12-19 |
| 67072 |
cas:2259318-50-6，MA-PEG4-VA-PBD ， ADC试剂 |
86 |
kx |
2024-12-19 |
| 67073 |
CAS: 2259318-55-1 - DBCO-(PEG2-VC-PAB-MMAE)2 |
57 |
WYQ |
2024-12-19 |
| 67074 |
CAS: 2768446-73-5，DBCO-Val-Cit-PAB-MMAE |
69 |
WYQ |
2024-12-19 |
| 67075 |
MC-vc-PAB-C6-a-amanitin， ADC试剂 |
60 |
kx |
2024-12-19 |
| 67076 |
cas:663598-98-9，2,5-dioxopyrrolidin-1-yl 4-methyl-4-((5-nitropyridin-2-yl)disulfanyl)pentanoate，ADC定制 |
76 |
wyh |
2024-12-19 |
| 67077 |
cas:2873452-49-2 MC-EVCit-PAB-MMAE |
80 |
zyl |
2024-12-19 |
| 67078 |
2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate，ADC定制 |
86 |
wyh |
2024-12-19 |
| 67079 |
cas:159857-70-2 MC-Val-Cit-Doxorubicin |
109 |
zyl |
2024-12-19 |
| 67080 |
Gly3-vc-PAB-MMAE， ADC试剂 |
87 |
kx |
2024-12-19 |
| 67081 |
CAS: 1869126-64-6， Azido-PEG4-Val-Cit-PAB-MMAE |
69 |
WYQ |
2024-12-19 |
| 67082 |
cas:2353409-54-6 ， Mal-amido-PEG8-Val-Gly，ADC定制 |
83 |
wyh |
2024-12-19 |
| 67083 |
Azido-PEG4-Val-Ala-PAB-PNP |
84 |
zyl |
2024-12-19 |
| 67084 |
NOTA-(NGR)2 NOTA偶联NGR二聚体 |
72 |
h |
2024-12-19 |
| 67085 |
1-(2,5-dioxopyrrolidin-1-yloxy)-4-((5-nitropyridin-2-yl)disulfanyl)-1-oxobutane-2-sulfonic acid，ADC定制 |
82 |
wyh |
2024-12-19 |
| 67086 |
CAS: 1343476-44-7，Val-Ala-PAB-OH |
70 |
WYQ |
2024-12-19 |
| 67087 |
MC-PBD， ADC试剂 |
81 |
kx |
2024-12-19 |
| 67088 |
Mal-Val-Ala-PAB的介绍 |
80 |
zyl |
2024-12-19 |
| 67089 |
DOTA-K-A9 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)结合肽A9 |
66 |
h |
2024-12-19 |
| 67090 |
Azide-PEG3-Val-Cit-PAB-MMAF，叠氮-三聚乙二醇-Val-Cit-PAB-MMAF |
68 |
WYQ |
2024-12-19 |
| 67091 |
Arm-DOTA-B72.3 |
68 |
h |
2024-12-19 |
| 67092 |
cas:1884577-99-4 Boc-Val-Ala-PAB |
84 |
zyl |
2024-12-19 |
| 67093 |
(Lys(DOTA)4)BVD15 DOTA偶联神经肽Y(NPY)类似物 |
119 |
h |
2024-12-19 |
| 67094 |
1801838-28-7，Mc-vc-PAB-SN38，化合物MC-VC-PAB-SN38 |
76 |
kx |
2024-12-19 |
| 67095 |
DOTA-PPI 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-官能化的聚(丙烯亚胺)(PPI)糖树枝状分子 |
76 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询